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ABSTRACT

CARDIAC SPECIFIC TRANSGENIC INHIBITION OF
NUCLEAR FACTOR - KappaB (NF-KB) MITIGATES ADVERSE CARDIAC
REMODELING AND AMELIORATES CARDIAC DYSFUNCTION IN
DOXORUBICIN-INDUCED CARDIOMYOPATHY

Santosh Kumar Sanganalmath
April 29, 2010

Background

The

anthracycline

doxorubicin

(DOX)

is

widely

used

as

an

effective

antineoplastic drug. Cardiotoxicity leading to congestive heart failure is the
primary factor limiting the clinical use of DOX. However, although a variety of
approaches to protect the heart against DOX-induced cardiotoxicity have been
attempted; treatment to prevent short and long term DOX-induced cardiac
damage remains limited. Currently, there is no specific therapeutic strategy
against this severe disease. Cardiac inflammation and myocardial apoptosis is
known to contribute to DOX-induced cardiomyopathy. The nuclear factor-kappaB
(NF-KB) is a part of the innate immune system and is involved in cardiac stress
reactions. Since NF-KB might playa significant role in cardiac inflammatory
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signaling and apoptosis, we investigated whether or not NF-KS is involved in
DOX-induced cardiotoxicity.
Methods and results
Age-matched wild-type (WT), nontransgenic littermates (NTg) and inhibitory
kappaS transgenic mice (IKS Tg) mice were divided into six groups based on
whether the mice receive either DOX or vehicle. DOX was injected at a dose of
7.5 mg/kg intraperitoneally (i.p.) 2 times over 2 wks. Group I, WT (vehicle, n=6);
group II, NTg (vehicle, n=6); group III, Tg (vehicle, n=6); group IV, WT (DOX,
n=14); group V, NTg (DOX, n=14); and group VI, Tg (DOX, n=11). Groups I, II
and III served as control mice and received injections of saline as vehicle. 14
days after DOX therapy, cardiac function was assessed by echocardiography
and hemodynamics using a micro conductance Millar catheter. Following
invasive hemodynamics, the mice were euthanized and heart and lung weights
were noted and hearts were perfusion fixed for pathology and morphometry. The
left ventricular (LV) tissue was harvested for myocardial protein expression of
pro inflammatory cytokines and proapopotic markers. DOX injection in WT and
NTg mice resulted in significant impairment in LV function as evidenced by a
decrease in LV ejection fraction (LVEF), LV systolic pressure (LVSP), LV rate of
pressure development and pressure decay (±dP/dt) and an increase in LV enddiastolic and end-systolic diameters, LV end-diastolic pressure and LV enddiastolic volume (LVEDV). Furthermore, WT and NTg mice after DOX therapy
showed signs of congestive heart failure as evidenced by an increase in lung
weight and development of pulmonary edema, which was also associated with
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signs of adverse ventricular remodeling (increase in chamber diameters and
decrease in wall thickness). In contrast to these findings, the heart weight,
LVEDP, LV intrinsic diameters, LVEDVand lung weight were reduced, whereas
the ± dP/dt, LVSP and LVEF were increased towards normal levels in IKB Tg
group.
In order to examine the effects of cardiac specific inhibition of NF-KB on
inflammatory response and myocardial apoptosis, LV samples were analyzed for
the protein expression of key inflammatory cytokines [tumor necrosis factor-a
(TNF-a), interleukin-6 (IL-6) and inducible nitric oxide synthase (iNOS)] and
proapoptotic proteins (Bax and p53) after DOX therapy. In WT and NTg hearts,
therapy with DOX was associated with an increase in inflammation and
apoptosis, as indicated by an up-regulation of TNF-a, IL-6, iNOS, Bax and p53.
In contrast, IKB Tg mice showed decreased expression of proinflammatory
cytokines and proapoptotic proteins. Furthermore, survival rate was significantly
higher in IKB Tg mice than in WT and NTg mice 14 days after DOX injection
(73% vs 43%, P < 0.05).

Conclusions
Cardiac specific inhibition of NF-KB improves LV function and attenuates adverse
cardiac remodeling in DOX-induced cardiomyopathy. These beneficial effects of
inhibition of NF-KB may be due to the decrease in the development of cardiac
inflammation and myocardial apoptosis in DOX-induced cardiotoxicity. These
findings may have important therapeutic implications of NF-KB in DOX-induced
congestive heart failure.
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CHAPTER I

INTRODUCTION

Doxorubicin (DOX) was first isolated in early 1950s and is considered one of the
most effective antineoplastic agents used in the treatment of solid and
hematopoietic tumors. However, this drug has proven to be a double-edged
sword since it can also cause severe cardiotoxicity leading to a dilated
cardiomyopathy, which results in congestive heart failure that is usually refractory
to common medications (1-3). Therefore, several investigators are currently
focusing their research to better understand the mechanisms underlying DOX's
cardiotoxicity. This may enable development of therapies, which may potentially
prevent and/or treat the heart failure it causes. Although the precise cellular
mechanisms responsible for the cardiotoxic effects of DOX remain enigmatic, it is
believed that the antitumor activity of DOX is likely to be distinct from the
mechanism of its cardiotoxicity (4, 5). It has been suggested that the DOXinduced cardiomyopathy may be due to the formation of reactive oxygen species,
expression of proinflammatory genes, apoptosis, and altered molecular signaling
(2, 3, 6). Until to date, taking these various mechanisms into consideration, a
variety

of approaches, which were aimed at preventing or mitigating the cardiotoxicity of
DOX have been tried, but so far, the ability of these treatments to protect the
heart from damage has not been successful. Therefore, to understand the
pathogenesis of DOX-induced cardiac dysfunction, inflammation and apoptosis,
we investigated the activation of NF-KB in myocardium.

NF-KB, a ubiquitous transcription factor, was first identified as a regulator of the
expression of the kappa light-chain gene in murine B lymphocytes (7) but has
subsequently been found in many different cells. NF-KB is found to be activated
by a wide range of inducers, such as cytokines, ultraviolet irradiation, and
chemotherapeutic agents including DOX. In quiescent cells, NF-KB is maintained
as an inactive form in the cytoplasm where it is bound to IKB inhibitor proteins,
which prevent NF-KB from entering the nuclei. Upon cellular activation by
extracellular stimuli, IKB is phosphorylated and proteolytically degraded by
proteases. This proteolytic process causes the release and translocation of NFKB complex into the nucleus, where it can mediate gene transcription by binding
to specific sequences in the promoter regions of its target genes. Products of
these target genes initiate or regulate inflammatory responses, apoptosis and
carcinogenesis. NF-KB promotes or inhibits programmed cell death (8, 9). The
opposing effects of NF-KB are dependent on cell type and/or the nature of stimuli.
It remains unclear whether NF-KB regulates inflammation and myocardial
apoptosis in DOX-induced cardiomyopathy. Therefore, we speculated that
suppression of inflammation and apoptosis may largely rescue DOX-triggered
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cardiotoxicity. In the present study, we induced DOX cardiomyopathy in a novel
mouse model, which can specifically inhibit NF-KB signaling pathway in the heart
and examined the effect of NF-KB inhibition on the following: (1) preservation of
the systolic and diastolic heart dysfunction; (2) mitigation of inflammatory
response; (3) attenuation of cardiomyocyte apoptosis; and (4) prevention of
mortality.
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CHAPTER II

BACKGROUND AND LITERATURE REVIEW

DOX as an Anticancer Agent

DOX belongs to a group of anthracycline drugs, which was originally isolated
from the pigment-producing bacterium Streptomyces peucetius in the early
1950s. DOX is one of the most effective anticancer agents (10) used in the
treatment of various neoplasms including acute leukemia, Hodgkin's, and nonHodgkin's lymphoma, and breast cancer. Although DOX is an effective
anticancer agent, it can cause tumor cell resistance and cardiotoxicity leading to
dilated cardiomyopathy and congestive heart failure, which is refractory to
common medications (11-14). In recent years, the use of higher doses of DOX
has dramatically increased the incidence of dilated cardiomyopathy. Figure 1
depicts the chemical structure of DOX in which the side chain terminates with a
primary alcohol. Although the precise mechanisms of action of DOX on tumor
cells have not been fully understood, various mechanisms have been suggested
by investigators such as: generation of reactive oxygen species leading to DNA
damage and peroxidation of lipids; inhibition of protein synthesis by interacting
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with DNA; inhibition of topoisomerase II, resulting in apoptosis and DNA
breakdown; cross-linking and alkylation of DNA, and blocking DNA strand
separation and helicase activity (15, 16). The critical component of the antitumor
activity of DOX is by generation of reactive oxygen species and by DNA
replication. DOX interacts with mitochondrial enzymes via their quinone ring and
produces huge amount of reactive oxygen species (17, 18). Furthermore, DOX
can directly act on DNA base pairs, inhibit DNA topoisomerase II, and lead to
DNA replication (19-21).

o

OH

o
OH

o

OH

Figure 1: Chemical structure of DOX: DOX consists of a tetra cyclic ring,
with the sugar daunosamine attached by a glycosidic linkage. Structurally,
doxorubicin is related to daunorubicin and differs only in hydroxyl group
substitution (instead of hydrogen) at the alkyl side chain, at position '9' of
the 'A' ring.
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Epidemiology and Clinical Features of DOX-induced Cardiomyopathy
DOX-induced cardiomyopathy is similar to other forms of dilated cardiomyopathy
characterized by enlarged ventricles, dilation of all chambers, and presence of
mural thrombi in both ventricles. DOX causes both acute and chronic
cardiotoxicity. The acute effects occur in approximately 11 % of patients during or
soon after initiation of DOX treatment and are usually reversible. The symptoms
include arrhythmias (supraventricular tachycardia and ventricular premature
beats), hypotension, and nonspecific electrocardiographic changes (11, 22, 23).
The chronic cardiotoxic effects of DOX occur in approximately 2% of patients,
and the prognosis is dismal with a mortality rate >50%. In chronic DOX-induced
dilated cardiomyopathy, the condition

is typically irreversible leading to

congestive heart failure (11, 14).

Mechanisms of DOX-induced Cardiomyopathy: Antitumor Activity versus
Cardiotoxicity
The antitumor activity of DOX is mainly due to initiation of DNA damage via the
inhibition of topoisomerase II. DOX-induced cardiotoxicity involves multiple other
mechanisms including oxidative stress, mitochondrial functional impairment,
cellular necrosis, and induction of apoptosis (2, 16). Therefore, despite the fact
that the exact mechanism of DOX-induced cardiomyopathy still remains
unknown, most investigators believe that an increase in oxidative stress and
generation of reactive oxygen species (24-26), peroxidation of lipids (24, 27, 28),
and reductions in the levels of antioxidants and sulfhydryl groups (29-31), playa
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crucial role in the pathogenesis of DOX induced cardiomyopathy (24-26, 32). In
addition, various other mechanisms suggest that DNA breakdown and protein
synthesis (33-35); release of vasoactive amines (histamine, serotonin and
catecholamines) (36); alteration in adrenergic activity (37); mitochondrial
dysfunction (38); changes in Iysosomes (28); alterations in sarcolemmal Ca 2+
handling by Na+/K+ ATPase and Ca 2+-ATPase activities (39) (40); impairment of
mitochondrial enzymatic activity (41);

and production of highly reactive

peroxynitrate and nitric oxide and inactivation of myofibrillar creatine kinase (42,
43). Furthermore, DOX also induces apoptosis in vascular smooth muscle cells
and cardiomyocytes by activating caspases and DNA degradation (44-46), which
eventually results in cardiomyocyte loss and thus can exacerbate heart failure
(47-51). Figure 2 shows the proposed mechanisms of interaction between DOX
and Nuclear Factor - kappaS (NF-KS) in pathogenesis of dilated cardiomyopathy
and congestive heart failure.
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Proposed

Subcellular
Remodeling

mechanisms

of

DApoptosis

NF-KB

and

DOX-induced

cardiomyopathy leading to heart failure. DOX is known to increase
oxidative stress, which in turn leads to increase in inflammation,
subcellular remodeling and apoptosis via NF-KB dependent mechanism
that eventually results

in

progressive

congestive heart failure.
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dilated cardiomyopathy and

DOX-induced Toxicity - Why does DOX Target Heart?
As stated earlier, the exact mechanism of DOX-induced cardiotoxicity still
remains unclear. DOX is a highly lipophilic drug and has a relatively long half-life
in the body (16, 52). The presence of quinone ring in the DOX makes it prone to
the generation of free radicals by redox cycling. Under aerobic conditions, a
single electron reduction

in the DOX molecule causes formation of a

semiquinone free radical, which donates its unpaired electron to oxygen leading
to the formation of superoxide radical (26, 53). Mizutani et al. show that a
relatively small amount of DOX is sufficient to catalyze the generation of
numerous superoxide radicals (54). As cardiomyocytes constantly require high
energy phosphates and thus rely on oxidative phosphorylation, these cells are
more prone to apoptosis than any other cell in the body. Also, as cardiac
myocytes contains low levels of enzyme catalase, and DOX can readily
inactivate glutathione peroxidase-1 present in these cells, cardiomyocytes are
further more susceptible to DOX injury (55, 56). Li et al. show that DOX
decreases protein levels of cytosolic glutathione peroxidase in cardiomyocytes,
which is responsible for scavenging of free radicals (57). It should also be noted
that as cardiomyocytes are considered as terminally differentiated cells, any loss
of these cells due to necrosis or apoptosis results in paucity of contractile
elements, eventually leading to cardiac dysfunction. Additionally, Singal et al.
(58) suggests remodeling of subcellular organelles such as sarcolemma,
mitochondria, sarcoplasmic reticulum and myofibrils causes alteration in
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intracellular Ca 2+ dynamics and

leads to contractile dysfunction in the

cardiomyocytes (58).

Nuclear Factor - kappaS (NF-KS)

NF-KB was discovered in 1986 via its interaction with an 11-base pair sequence
in the immunoglobulin light-chain enhancer in murine B lymphocytes (59). It is a
widespread dimeric transcription factor that exists in the cytosol complexed to an
inhibitory kappaB (IKB) monomer. The complex of NF-KB consists of either a p50
(NF-KB1) or a p52 (NF-KB2) subunit complexed to another protein from the Rei
group [which includes p65 (ReIA), c-Rel and ReIB] (60, 61). NF-KB is activated by
various stimuli including ischemia, cytokines, hypoxia, free radicals and oxidants,
lipopolysaccharide (LPS), activators of protein kinase C, ultraviolet radiation, and
viruses (60). The activation of NF-KB due to these stimuli translocates NF-KB to
the nucleus, which in turn binds to specific DNA binding sites (called KB), present
within the promoter regions of various genes including those encoding p65, IKBa,
tumor necrosis factor-a (TNF-a), interleukin (IL)-2, IL-6, IL-8, interferon (IFN)-J3,
inducible nitric oxide synthase (iNOS), and several adhesion molecules (60, 61).
This activation of NF-KB is controlled by site-specific phosphorylation and
ubiquitination

of

IKB

proteins

that

target

IKB

for

proteasome-mediated

degradation (62). Although, there are currently seven known IKB isoforms (IKBa,
IKBJ3, IKBy, Bcl-3, IKBE, IKB-R, and IKB-L) (61), only IKBa and IKBJ3 have been
studied most extensively, and are thought to be the key regulators of NF-KB
nuclear translocation. Traenckner et al. show that phosphorylation of serine
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residues at positions 32 and 36 is critical for ubiquitination and degradation of
IKBa (63) with consequent release and nuclear migration of NF-KB.

Phosphorylation
ofhcB by
IcBlcina..

Ublqultination
ofhcB

Ub-Ub-Ub

Dewadatlon of hcB
by 28S proteasome

Figure 3: The NF-KB pathway is activated by various pathologic stimuli,
which leads to phosphorylation of IKB and proteolytic degradation by
proteases. This proteolytic process causes the release and translocation of
NF-KB complex into the nucleus, where it can mediate gene transcription
by binding to specific sequences in the promoter regions of its target
genes. Products of these target genes initiate or regulate inflammatory
responses, apoptosis and carcinogenesis. The figure also depicts the
overexpression of IKBa, which inhibits the process of phosphorylation of
IKB by IKB kinase thereby inhibiting the NF-KB pathway.
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Generation of IKBa

S32A, S36A

transgenic mice with Cardiac-Specific Inhibition

of NF-KB

To specifically determine the role of NF-KB in pathophysiologic processes
requires specific inhibition of the transcription factor in the heart in vivo, which
thus far has not been possible. As a result, the contribution of NF-KB to
cardiovascular pathophysiology in the intact animal has been inferred either from
correlative evidence (e.g., association of NF-KB activation with a certain
outcome) or by inhibition with pharmacologic agents of limited specificity (64, 65).
Although there are numerous pharmacologic agents to inhibit NF-KB, which are
available for in vivo use, none of these agents have sufficient specificity to
provide conclusive evidence of NF-KB function (64, 65). Therefore, in order to
determine whether expression of a transdominant mutant IKBa abrogates NF-KB
activation specifically in the heart, we have created a transgenic mouse with
cardiac-specific expression of IKBa

S32A, S36A

(Figure 3) (66). In this mouse model,

the a-MyHC promoter was chosen to drive the expression of IKBa

S32A, S36A

since

this promoter directs high level, cardiac-specific gene expression in a positionindependent, copy-number-dependent manner (67, 68). As demonstrated by
Dawn et aI., this IKBa

S32A, S36A

transgenic mouse exhibits normal cardiac

morphology and histology and the expression of the mutant IKBa completely
blocks NF-KB activation by both TNF-a and LPS (two important agents, which
elicits NF-KB activation and orchestrates NF-KB signaling) (68-70). Therefore,
these mice provide an in vivo system to study and conclusively determine the
role of NF-KB in specific cardiac pathophysiological states. In this mouse model,
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a transgene was constructed for the expression in the murine heart of a
transdominant human IKBa cDNA (with serine residues at positions 32 and 36
replaced by alanine, IKBa

S32A. S36A).

The human IKBa

S32A. S36A

cDNA was

released from the original plasmid (pSVK3) (71) by restriction digestion with Sma
I and subcloned between the S.S kb a-MHC promoter and the 736 bp human
growth hormone polyadenylation sequences (72) (Figure 4). Transgenic mice
were made by pronuclear microinjection of the isolated purified linear transgene
into the male pronuclei of fertilized mouse oocytes (FVB/N strain) (73). The
founder transgenic mice were genotyped by PCR, using a-MHC-specific primer
(S'-AAGCCT- AGCCCACACCAGAAATGACAGACA-3') and an IKBa-specific
primer (S'-AGTAGCCGCTCCTTC-TTCAGCCCGTC-3').

Not I

[Sal IISma I] [Sma IlSaII]

Not!

~------------------~

heBa. S32A,S36A

a-MyHC promoter

Hgh

5.5kb

Balli

736kb

Balli

Figure 4: Diagrammatic representation

of the

construct. The 1.1 kb human IKBa cDNA (IKBa

transgenic promoter

S32A, S36A)

was subcloned

between the 5.5 kb a-MyHC promoter and the 736 bp human growth
hormone (Hgh) polyadenylation signal. The cDNA was released from
plasmid pSVK3 by excision with Sma I and cloned into the Sal I restriction
site of the a-MyHC vector. The transgene was excised from the plasmid by
restriction with Not I and used for pronuclear microinjection.
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Uses of IKBa

S32A, S36A

transgenic mice

Although several pharmacologic inhibitors of NF-KB activation are currently
available, they lack specificity, and thus, do not yield valid results. For example,
dithiocarbamates are antioxidants and iron chelators (64), and therefore would
be expected to produce a multitude of effects, including inhibition of other
transcription factors like AP-1 (74) in addition to inhibition of NF-KB. Peptide
inhibitors of NF-KB that have been used in isolated cells (75) are not effective in
vivo. Furthermore, using pharmacologic inhibitors in vivo, it is impossible to

localize the effect of inhibition of NF-KB activity to a specific organ. The IKBa
S36A

S32A,

transgenic mouse provides a novel tool to investigate specifically and

conclusively the role of NF-KB in cardiac pathophysiology. As a result of the
cardiac-specific expression of the transgene, these mice enable assessment of
the role of NF-KB specifically in the heart. Accordingly, the IKBa

S32A, S36A

transgenic mice should be useful not only for signal transduction research, but
also to verify the utility and efficacy of new therapeutic approaches in modifying
NF-KB activity and in modulating the effects of TNF-a and LPS in the setting of
myocardial ischemia-reperfusion injury, heart failure, septic shock, cardiac
hypertrophy, atherogenesis, and acute coronary syndromes.
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CHAPTER III

FUNDAMENTAL QUESTION

Phenomenon

The prognosis of patients with DOX-induced cardiomyopathy and congestive
heart failure is dismal and mechanisms leading to this cardiotoxicity remain
elusive. Also, various approaches to protect the heart against this severe cardiac
damage have been unsuccessful.

Proposed Concepts

Although end-stage ischemic cardiomyopathies could be manageable by using
procedures such as revascularization and therapeutic angiogenesis, non ischemic
cardiomyopathies can only be treated radically by heart transplantation (76, 77).
Cardiac transplantation has several limitations such as availability of donors,
graft rejection and adverse effects of immunosuppressive medications (76, 77).
DOX is widely used as a broad-spectrum antineoplastic drug in the treatment of
both solid tumors and leukemia. Unfortunately, despite its broad spectrum
effectiveness, long-term therapy with DOX is associated with a high incidence of
a cumulative and irreversible dilated cardiomyopathy followed by congestive

15

heart failure, which is often fatal to the patients (2, 11, 78). The morphology of
the heart of DOX-induced cardiomyopathy is similar to dilated cardiomyopathy, in
which progressive heart failure and sudden cardiac death from ventricular
arrhythmia occur (79).

Experimental Design
To address these issues, a series of experiments were designed to test the
following hypothesis. The experimental protocol is shown in Figure 5.

day 0

BSL echocardiography
7.5 mgJkg DOX i.p.

14 days

7.5mglkg
DOXi.p.

day 14

1. Final echocardiography
2. In vivo Hemodynamics
3. Pathology & Morphometry
4. Western Irnmunoblotting:
Proinflarrmatory cytokines: TNF-a, IL-6, iNOS
Antiapoptotic: Bax, p53

Figure 5: Experimental Protocol. WT, NTg and IkB Tg mice were divided
into six groups based on whether the mice received either DOX or vehicle.
DOX was injected at 7.5 mg/kg dose intraperitoneally (i.p.) 2 times over 2
wks. Group I, WT (vehicle); group II, NTg (vehicle); group III, Tg (vehicle);
group IV, WT (DOX); group \I, NTg (DOX); and group VI, Tg (DOX).
Echocardiography was performed at baseline and at 2 wks after DOXlsaline
therapy. At the end of study period (2wks after first DOX dose), after an
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invasive hemodynamics, heart and lungs were pathologically assessed and
L V samples were frozen for the expression of proinflammatory cytokines
and apoptotic proteins.

Hypothesis
Sustained over-expression of proinflammatory cytokines provokes the induction
of cardiomyocyte apoptosis in DOX-induced cardiomyopathy, which contributes
to adverse ventricular remodeling and cardiac dysfunction eventually progressing
to congestive heart failure.

AIM #1: To test the hypothesis that cardiac-specific transgenic inhibition of NF-

KB mitigates doxorubicin-induced adverse ventricular remodeling and

cardiac dysfunction.
AIM #2: To test the hypothesis that cardiac-specific transgenic inhibition of NF-

KB

reduces

the

expression

of

proinflammatory

cytokines

in

doxorubicin-induced cardiomyopathy.
AIM #3: To test the hypothesis that cardiac-specific transgenic inhibition of NF-

KB

reduces

myocardial

apoptosis

cardiomyopathy.
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CHAPTER IV

AIM #1

Cardiac-Specific Transgenic Inhibition of NF-KB Mitigates Doxorubicininduced Adverse Ventricular Remodeling and Cardiac Dysfunction

AIM #1 ABSTRACT
Background
The use of the DOX is associated with adverse cardiac remodeling with impaired
ventricular function that can progress to congestive heart failure and has
important implications for survival. In spite of several pharmacologic and surgical
interventions for cardiomyopathy, many patients continue to experience a
progressive decline in cardiac function. Therefore, improved methods to
attenuate ventricular remodeling and function in dilated cardiomyopathy are
needed. Although NF-KB has been implicated in heart failure due to ischemia and
cardiac hypertrophy, its role on detrimental cardiac remodeling and cardiac
dysfunction in DOX-induced cardiomyopathy are unknown. We sought to
examine if cardiac specific transgenic inhibition of myocardial NF-KB activation
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could prevent structural cardiac remodeling and mitigate cardiac dysfunction in
dilated cardiomyopathy due to DOX treatment.

Methods and Results
Age-matched wild-type (WT, n=14), nontransgenic liUermates (NTg, n=14) and
IKB Tg (n=11) mice received intraperitoneal injections of DOX twice over 2 wks
(total dose of 15 mg/kg BW). Cardiac function and remodeling were assessed
using echocardiographic techniques and in vivo hemodynamic measurements.
Saline injected WT, NTg and IKB Tg mice served as controls. At 14 days after
DOX therapy, WT and NTg mice showed marked increase in heart weight, left
ventricular (LV) end-diastolic pressure (LVEDP), LV intrinsic diameters, LV enddiastolic volume (LVEDV) and reduction in rates of pressure development and
decay (± dP/dt), LV systolic pressure (LVSP) and LV ejection fraction (LVEF).

WT and NTg mice also showed signs of heart failure as evidenced by an
increase in lung weight and development of pulmonary edema. The heart weight,
LVEDP, LV intrinsic diameters, LVEDV and lung weight were reduced, whereas
the ± dP/dt, LVSP and LVEF were increased towards control levels in IKB Tg
group compared with WT and NTg groups. Total mortality during 2 wk follow-up
period averaged 57% in WT and NTg mice and 27% in IKB Tg mice.

Conclusions
The results suggest that cardiac specific abrogation of NF-KB in DOX-induced
cardiomyopathy decreases mortality and has beneficial effects on LV function
and cardiac remodeling in congestive heart failure. These findings may have
important therapeutic implications of NF-KB in DOX-induced cardiac dysfunction.
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INTRODUCTION

Heart failure induced by DOX has been characterized by bilateral ventricular
enlargement followed by thinning of the ventricular wall, and reduction in the
LVEF (80). After DOX treatment, the LVEF measured by echocardiography is
shown to be decreased from 54% to 35% while the cardiac output decreased
from 5.6 to 3.9 Llmin in 2 wks. Dilation of the ventricles as evidenced by increase
in LV end-diastolic and end-systolic diameters (LVEDD and LVESD) has been
shown to increase by 10% and 30%, respectively (80). In recent years, a growing
body of evidence indicates the crucial role of NF-KB as a central mediator of
various cardiac pathologies. Therefore, complete inhibition of this pathway will be
beneficial in the setting of stress and heart disease. In these lines, several
investigators have used the classic model of NF-KB activation to develop
therapeutic strategies that inhibit various steps in the canonical signaling
cascade. The appreciation of the importance of the NF-KB family of transcription
factors in cardiac disease has stimulated the development of multiple therapeutic
strategies based on modifying this signaling pathway. The aim of this study was
to examine the effects of cardiac specific inhibition of NF-KB activation on the
improvement of cardiac function and attenuation of adverse cardiac remodeling
in DOX-induced cardiomyopathy and congestive heart failure.
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MATERIALS AND METHODS

Animals
All animal studies were performed in accordance with the guidelines of the
National Institutes of Health (NIH) Guide for the Care and Use of Laboratory
Animals and University of Louisville. Mice were housed in a facility with a 12
hr/12 hr light/dark cycle and were fed rodent chow and water ad libitum. The
room

was

kept

specific

pathogen-free.

Age-matched

wild-type

(WT),

nontransgenic littermates (NTg) and IkB Tg mice were divided into six groups
based on whether the mice receive either DOX or vehicle. We injected a 7.5
mg/kg dose of DOX intraperitoneally (i.p.) 2 times over 2 wks. Group I, WT
(vehicle, n=6); group II, NTg (vehicle, n=6); group III, Tg (vehicle, n=6); group IV,
WT (DOX, n=14); group V, NTg (DOX, n=14); and group VI, Tg (DOX, n=11).
Groups I, II and III served as control mice and received injections of saline as
vehicle.

Echocardiography
Echocardiography was performed prior to DOX injection (baseline) and at the
time of sacrifice (2 wks after the first DOX dose). Mice were weighed and
anesthetized with isoflurane (ISF) inhalation. Induction was performed over 2
minutes with 3% ISF in 100% O2 . Anesthesia was maintained with 1% ISF in
100% O2 at a flow rate of 1 Llmin via a small nose cone. The mice were kept on
a heating pad in a supine position with a slight tilt to the left decubitus position.
The heating pad temperature was adjusted to maintain mice rectal temperature
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between 37 and 38 0 C. The anterior chest was shaved and the mice were placed
in the left lateral decubitus position. Echocardiographic images were obtained
using a Philips HOI 5000 SonoCT ultrasound system equipped with a 12-5 MHz
phased-array probe fitted with a 0.3 cm standoff and a 15-7 MHz broadband
linear probe. LV structure and function were assessed by previously validated
two-dimensional, M-mode, and Doppler echocardiographic techniques.

Echocardiography - Analysis
Digital images were analyzed off-line by a single blinded observer using the
ProSolv image analysis software (ProSolv, Inc., Indianapolis, IN). At least three
consecutive beats were analyzed and averaged for the reported measurement.
M-mode LV diameter and wall thickness:
LVEDD and LVESD were measured from M-mode tracings obtained at the midpapillary level and analyzed according to the modified American Society of
Echocardiography standards (posterior wall leading-edge to leading-edge and
anterior wall trailing-edge to trailing-edge).
2-D Cross-sectional Anatomy:
LV areas in diastole and systole were measured using the American Society of
Echocardiography standards.
);- Teichholz EDV: EDV was calculated using the Teichholz formula:
EDV (IJL) = [7/ (2.4+LVEDD)] x (LVEDD3)
);-

LVEF was calculated as:
EF (%)

=[(LVEDD2-LVESD2)/LVEDD2] x 100
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Hemodynamics

The hemodynamic studies were performed just before euthanasia (2 wks after
the first DOX dose). Animals were anaesthetized (thiopental 50 mg/kg; i.p.),
intubated and artifiCially ventilated. A 1.4 F microconductance pressure catheter
(Millar-Instruments, Inc., Texas, USA) was inserted into the right carotid artery
and advanced into the LV under pressure control as described (81). After
stabilization for 15 mins, the signals were recorded continuously with a
Powerlab/4SP AID converter (AD Instruments), stored, and displayed on a
personal computer. The maximal LVSP an LVEDP, maximal slope of systolic
pressure increment (+dP/dt) and diastolic pressure decrement (-dP/dt) were
calculated and corrected according to in vitro and in vivo volume calibrations with
a cardiac pressure-volume analysis program (PVAN 2.9; Millar instruments).

Pathology and Morphometry

Animals were euthanized at 2 wks after the first dose of DOX therapy. Following
euthanasia, the heart was removed, washed in cold PBS, and weighed with an
analytical balance. Pathologic heart weight was noted. The heart was then
cannulated via the aorta and retrogradely perfused at a constant perfusion
pressure equivalent to 100 cm H2 0. The heart was perfusion-fixed in 10%
neutral-buffered formalin and was sectioned serially perpendicular to the
longitudinal axis, processed, and embedded in paraffin. The morphometric
variables were calculated by computerized planimetry (Image-Pro Plus) of digital
images of three Masson's trichrome-stained serial sections taken at 0.5 to 1.0
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mm intervals along the longitudinal axis. The midsection was used to measure
LV chamber diameter. LV wall thickness was also measured. All anatomical
variables were corrected according to a uniform sarcomere length.

Statistical Analysis

Data are reported as mean ± SEM. Data were measured with a two-way (time
and group) ANOVA followed by Student's t tests with the Bonferroni correction
(82). A 'P' value less than 0.05 was considered statistically significant. All
statistical analyses were performed using the SPSS software (version 8, SPSS,
Inc., Chicago, IL). Mortality was analyzed using Kaplan Meier survival analysis.
Comparison of Kaplan Meier survival curves was performed by using a log-rank
test.

RESULTS
Survival Rates

Survival rates were compared between

wr,

NTg and IKB Tg mice up to 14 days

after DOX injection. As a consequence of preserved LV function in IKB Tg mice
after DOX, survival was significantly higher in IKB Tg mice than in
mice. Out of 28 mice that received DOX therapy in
groups, 8 mice died in

wr

wr and

NTg

(n=14) and NTg (n=14)

wr and 8 mice in NTg groups at the end of 2 wk follow-up

period, which corresponds to 57% mortality. We lost 3/11 mice during the 2 wk
period in IKB Tg group. There was no animal loss in the vehicle treated groups of
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18 mice.

The data on mortality, as well as Kaplan Meier Survival plot for all

groups is shown in Figure 6.

Figure 6: Survival curves after DOX injection in WT, NTg and IKB Tg mice at
2 wks after DOX therapy. Survival curves were created by Kaplan-Meier
method and compared by log-rank test. Percentages of surviving WT, NTg
and IKB Tg mice were plotted.
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Clinical Manifestations and Pathologic Changes in Organs after DOX
Treatment

wr

and NTg mice had clinical signs of congestive heart failure, i.e. lung

congestion as reflected by the increased lung weight, ventricular chamber
enlargement, pulmonary edema and ascites. After echocardiography and
hemodynamic studies, mice were euthanized with a lethal injection of sodium
pentobarbital (50 mg/kg) intraperitoneally, and heart and lung weights were
measured in all the groups. Although body weight was the similar in all groups,
heart and lung weights were less in IKB Tg mice than in

wr and

NTg mice after

DOX administration (Figures 7A and 7B). Gross anatomical examinations at the
end of the study period showed the hearts of DOX-treated

wr

and NTg mice

were dilated and both the atria and ventricles were enlarged and hypertrophic
(Figure 8). To confirm the improvement of the morphology of the hearts in IKB Tg
mice, we examined Masson's trichrome-stained serial sections taken at 0.5 to 1.0
mm intervals along the longitudinal axis at 2 wks after the DOX therapy. As
shown in Figure 9, hearts in

wr and NTg groups showed thin LV walls compared

with the control hearts, whereas hearts in IKB Tg groups showed thicker LV walls
than in

wr and

NTg mice, being a similar morphology to that of a normal heart.

Thus, we confirmed that DOX induces cardiomyopathy and that inhibition of NFKB improved morphology and function of the DOX injured heart.
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Figure 7: Pathologic heart weight (A) and lung weight (B) in vehicle-treated
(A), WT OOX-treated (B), NTg DOX-treated (C) and IKB Tg OOX-treated (0)
mouse heart at 2 wks after OOXlsaline therapy_ The' IKB Tg mice showed
decrease in heart and lung weights compared to WT and NTg mice after
DOX treatment.
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Figure 8: Gross anatomical changes in vehicle-treated (A), WT DOX-treated
(B), NTg DOX-treated (e) and IKB Tg DOX-treated (D) mouse heart at 2 wks
after DOXIsaline therapy. The IKB Tg heart exhibits less chamber dilation
and thicker ventricular walls compared to WT and NTg mice.
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A)

C)

Figure

D)

9: Assessment of LV remodeling.

Representative Masson's

trichrome-stained myocardial sections from vehicle-treated (A), WT OOXtreated (B), NTg OOX-treated (C) and IKB Tg OOX-treated (0) mice at 2 wks
after OOXlsaline therapy. The L V cavity is smaller and the ventricular wall
is thicker in the IKB Tg mice compared with the WT and NTg mice.
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IKB Tg Mice Are Resistant to DOX-induced Cardiac Dysfunction
Echocardiography

Before DOX injection (baseline), all variables of LV function, measured by
echocardiography, were similar in WT, NTg and IKB Tg groups (Figure 10);
indicating that the extent of injury sustained during DOX therapy was
comparable. WT and NTg mice exhibited a progressive deterioration in LVEF
from baseline to 2 wks; this worsening in LVEF was attenuated in IKB Tg mice,
resulting in a markedly greater LVEF at 2 wks compared with WT and NTg mice.
During follow-up, LVEDD and LVEDV increased progressively in all groups,
consistent with postinfarct LV remodeling (Figure 10). However, in IKB Tg mice
LVEDV at 2 wks was significantly smaller compared with WT and NTg mice,
indicating sustained improvement in LV remodeling with NF-KB inhibition (Figure
10). Shown in Figure 11 are representative two-dimensional and M-mode
echocardiographic tracings from a WT, NTg and IKB Tg animal at 2 wks after
DOX treatment. In contrast to the LV wall motion in the control group (Figure
11A), the waveforms from the WT (Figure 11 B) and NTg (Figure 11 C) animals
clearly demonstrated blunted anterior and posterior wall motion, consistent with
decreased EF (P < 0.05), indicating a decrease in myocardial performance in WT
and NTg mice after DOX treatment. The decrease in the LV wall motion was
improved in IKB Tg mice (Figure 11 D).

30

D

WT + Veh (n=6)

~ NTg + Veh (n=6)

D NTg + DOX (n=6)
~ WT + DOX (n=6) mJ Tg + DOX (n=8)
_

Tg + Veh (n=6)

* P < 0.05 vs WT+DOX, § P< 0.05 vs NTg+DOX
A)

B) 100

100

80

80
L

~
0

§

§

,:r;

*

60

.....J
::J..

.*

60
T

40

40

20

20

0

C)

O~

Baseline

14 days

D)
,:r,:

§

v

*

4

E
E

E
E

3

Baseline

10:

,
14 days

Quantitative

4

§

3

*

2

,

o

14 days

6...------------------------.
5

r
2

Figure

Baseline

6

5

__-LillU~L-~~~_ _~

O~

____'_~'_.L..I!!!!L_~=:!'_C1!!!I..------'

Baseline

assessment

of

LV

systolic

14 days

function.
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L VESV (D) in WT, NTg and IKB Tg mice at baseline and at 2 wks after
DOXlsaline therapy. The IKB Tg mice showed an improved LVEF and a
decreased L VEDV at 2 wks after DOX therapy. Also, compared with the WT
and NTg hearts, the IKB Tg mouse exhibited smaller LV diameters. Data are
mean±SEM.
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A)

D)

32

Figure 11: Echocardiographic data. (A-D) Representative 2-dimensional
and M-mode echocardiographic images from a normal healthy mouse with
vehicle injection (A), WT DOX-treated (B), NTg DOX-treated (C), and IKB Tg
DOX-treated (D) mice at 2 wks after DOXlsaline therapy. Compared with the
WT and NTg hearts, the IKB Tg heart shows a smaller LV cavity and thicker
anterior wall. Contractile activity in the anterior wall is present in the IKB Tg
heart and virtually absent in the WT and NTg heart.

Hemodynamics
Hemodynamic parameters obtained from the different experimental groups 2 wks
after DOX injection are shown in Figure 12. WT and NTg mice showed LV
dysfunction with decreased LVSP, decreased rate of LV pressure development
(+d P/dt), pressure decay (-dP/dt) and an elevated LVEDP compared to control
animals. The LVEDP was reduced, whereas the ±dP/dt and LVSP was increased
towards sham levels in IKB Tg group compared with WT and NTg mice.
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Figure 12: Hemodynamic measurements of LVSP (A), LVEDP (B), +dP/dt (C)
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Cardiac Specific Transgenic Inhibition of NF-KB Halts LV Remodeling in
DOX-induced Dilated Cardiomyopathy:

By echocardiography, the LVEDD and LVESD were markedly increased in \NT
and NTg mice after DOX injection, as shown in Figures 10 and 11. However, in
IKB Tg mice, LV dilatation after DOX therapy was prevented, and LVEDD and
LVESD were significantly smaller than in \NT and NTg mice. Similar to these
findings, morphometric assessment of heart sections showed smaller LV
chamber diameter in IKB Tg mice treated with DOX when compared with \NT and
NTg groups. Also, wall thickness was significantly improved in IKB Tg mice
treated with DOX when compared to \NT and NTg mice (Figure 13).

CONCLUSIONS:

This study was undertaken to test the beneficial effects of cardiac specific
transgenic inhibition of NF-KB on LV function and ventricular remodeling in DOXinduced cardiomyopathy. From the results obtained in this study, the following
conclusions can be drawn 1)

Cardiomyopathy in mice due to DOX therapy was evidenced by
decrease in LVSP, increase in LVEDP and LV diameters followed by
LV dilation. These changes in LV lead to impairment in systolic and
diastolic function.

2)

In view of observed alterations in cardiac morphology in \NT, NTg and
IKB Tg hearts, it is suggested that ventricular remodeling, systolic and
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diastolic dysfunction in CHF due to DOX therapy, may be partly due to
the NF-KB activation in the failing heart.
3)

Cardiac specific transgenic inhibition of NF-KB significantly decreased
mortality and improved the LV function and reversed the adverse
ventricular remodeling due to DOX and such changes may be
indirectly due to decrease in preload and afterload.
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CHAPTER V

AIM #2

Cardiac-Specific Transgenic Inhibition of NF-KB reduces the Expression of
Proinflammatory Cytokines in Doxorubicin-induced Cardiomyopathy

AIM #2 ABSTRACT
Background

The NF-KB proteins are known to playa critical role in mounting the immune
response and in controlling genes of proinflammatory cytokines. The expression
of innate immune response proteins such as tumor necrosis factor-a (TNF-a),
interleukin (IL-6) and inducible nitric oxide synthase (iNOS) occurs in the cardiac
tissue of humans and experimental animals with heart failure. Therefore, due to
the profound cardiodepressant effects of proinflammatory cytokines, there is a
well-justified interest to identify the signaling pathways that drive the expression
of these proteins in cardiomyocytes.
Methods and Results

Age-matched wild-type (\NT, n=14), nontransgenic littermates (NTg, n=14) and
IKB T9 (n=11) mice received intraperitoneal injections of DOX twice over 2 wks
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(total dose of 15 mg/kg BW). Myocardial protein expression of proinflammatory
cytokines, TNF-a, IL-6, and iNOS were assessed by Western immunoblotting. At
14 days after DOX therapy, we found a significant increase in the expression of
TNF-a, IL-6, and iNOS in NTg mice treated with DOX. This increase in
expression of TNF-a, IL-6, and iNOS were significantly attenuated by DOXtreated IKB Tg mice.
Conclusions

Cardiac specific inhibition of NF-KB has preventive effects on cardiac
inflammation induced by DOX. These findings suggest that NF-KB is detrimental
in DOX-induced inflammatory processes. These insights might have useful
implications for future studies utilizing NF-KB antagonists for treatment of human
DOX-induced cardiomyopathy.

INTRODUCTION

The activation and translocation of NF-KB to the nucleus is followed by
transcription of various pro-inflammatory genes, including tumor necrosis factor-a
(TNF-a), interleukin (IL-6) and inducible nitric oxide synthase (iN OS) (83, 84).
NF-KB acts on genes for proinflammatory cytokines, chemokines (chemotactic
cytokines that attract inflammatory cells to sites of inflammation), enzymes that
generates

mediators

of inflammation,

immune

receptors,

and

adhesion

molecules that playa crucial role in the initial recruitment of leukocytes to sites of
inflammation. The activation of NF-KB leads to a coordinated increase in the
expression

of

many

proinflammatory
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genes

whose

products

mediate

inflammatory and immune responses. Therefore, NF-KB is an obvious target for
new types of anti-inflammatory treatment. Although various proinflammatory
cytokines are not constitutively expressed in the normal heart (85, 86), the failing
heart produces robust quantities of these cytokines that can be found both in the
heart and in the peripheral circulation of patients with heart failure. Upregulation
and production of these cytokines represent an intrinsic or an innate stress
response against myocardial injury (87). When selectively overexpressed in
hearts of mice, these cytokines effects the development of a dilated
cardiomyopathy that closely mimics the pathophysiology seen in human failing
hearts (88, 89). One pathway that appears to playa role in proinflammation in
dilated cardiomyopathy is the ubiquitous transcription factor NF-KB. Therefore,
the objective of this study was to investigate the role of cardiac specific inhibition
of NF-KB in DOX-induced myocardial inflammation. Using a well established
model of DOX-induced cardiomyopathy and heart failure in mice, we examined
whether

the

inflammatory

processes

associated

with

DOX-induced

cardiomyopathy is a result of an increase in the expression of proinflammatory
cytokines.

MATERIALS AND METHODS
Animals

All animal studies were performed in accordance with the guidelines of the
National Institutes of Health (NIH) Guide for the Care and Use of Laboratory
Animals and University of Louisville. Mice were housed in a facility with a 12
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hr/12 hr light/dark cycle and were fed rodent chow and water ad libitum. The

room

was

kept

specific

pathogen-free.

Age-matched

wild-type

(WT),

nontransgenic littermates (NTg) and IkB Tg mice were divided into six groups
based on whether the mice receive either DOX or vehicle. We injected a 7.5
mg/kg dose of DOX intraperitoneally (Lp.) 2 times over 2 wks. Group I, WT
(vehicle, n=6); group II, NTg (vehicle, n=6); group III, Tg (vehicle, n=6); group IV,
WT (DOX, n=14); group V, NTg (DOX, n=14); and group VI, Tg (DOX, n=11).
Groups I, II and III served as control mice and received injections of saline as
vehicle. At the end of study period (14 days after first DOX dose), heart was
removed, the atria and the large vessels were carefully trimmed, and the
ventricles were separated. The LV (including septum) was dissected and the
tissue was frozen at -70°C for protein expression of TNF-a, IL-6 and iNOS.

Preparation of Homogenates and Cytosolic and Membranous Fractions
Homogenates, cytosolic and membranous proteins of heart tissue was prepared
as previously described (90-92). Briefly, myocardial samples were homogenized
for 2 x 10 seconds in buffer A [25 mmolll Tris . HCI (pH 7.5), 0.5 mmolll EDTA,
0.5 mmolll EGTA, 1 mmolll phenylmethylsulfonyl fluoride, 2 IJmolil leupeptin,
1 IJmolil pepstatin, 1 IJmolil aprotinin, 10 mmolll NaF, and 100 IJmolil dephostatin]
as total cellular homogenates. After that, homogenates were centrifuged at
14,000 g for 15 mins, and the resulting supernatants were collected as cytosolic

fractions. Pellets were incubated in a lysis buffer (buffer A + 1% Nonidet P-40)
for 4 hrs, centrifuged, and the resulting supernatants used as membranous
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fractions. The protein content in the homogenates, cytosolic, and membranous
fractions was determined using the Bradford technique (Bio-Rad).

Western Immunoblotting

The expression of proteins was assessed using standard SDS-PAGE Western
immmunobiotting techniques as previously published methods (90-92). Briefly, 70
I-1g of cytosolic proteins or membranous proteins were electrophoresed on a
denaturing SDS gel for 2 to 3 hrs. After electrophoresis, the proteins on the gel
were electrophoretically transferred to nitrocellulose membranes (Bio-Rad)
overnight at 4°C. Gel transfer efficiency was carefully recorded by making
photocopies of membranes dyed with reversible Ponceau staining; gel retention
was determined by Coomassie blue staining as previously described. The
membranes were incubated in 5% nonfat dry milk in TBST buffer (10 mmolll
Tris-HCI [pH 7.2], 0.15 molll NaCI, and 0.05% Tween-20) followed by incubation
with specific primary antibodies (Santa Cruz Biotechnology, Inc). After extensive
rinsing with TBST buffer, blots were incubated with HRP-conjugated anti-rabbit or
anti-mouse secondary antibodies and developed with the use of an enhanced
chemiluminescence system (ECl kit, Amersham). After washing with TBST
buffer, blots were air-dried and exposed to Kodak films in x-ray cassettes with
intensifying screens.

The

signals

detected

by

immunoblotting

and

the

corresponding records of Ponceau stains of nitrocellulose membranes were
quantitated using an image scanning densitometer (Personal PI, Molecular
Dynamics). Anti TNF-a, anti Il-6 antibodies were purchased from Santa Cruz
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Biotechnology, Inc., and anti iNOS antibodies were purchased from BD
Transduction Laboratories.

Statistical Analysis

Data are reported as means ± SEM as previously described methods (90-92).
Measurements were analyzed by ANOVA followed by unpaired Student's t tests
with the Bonferroni correction. In all Western blot analyses, the content of the
specific protein of interest was expressed as a percentage of the corresponding
protein in the anterior LV wall of NTg vehicle-treated mice.
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Figure 14: Western blots of membranous (Panel A) and cytosolic (Panel B)
fraction of TNF-a protein at 2 wks after DOXlsaline treatment in NTg mice
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from 5 individual hearts per group. Data are mean
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± SEM.
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Figure 15: Western blots of IL-6 (Panel A) and iNOS (Panel B) proteins at 2
wks after DOXlsaline treatment in NTg mice compared with IKB Tg mice.
Bar graph shows densitometric quantification from 5 individual hearts per
group. Data are mean ± SEM.
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RESULTS
TNF-a, IL-6 and iNOS protein expression
Protein expressions of both membranous and cytosolic fractions showed a
markedly elevated expression of TNF-a after DOX treatment in NTg mice.
However, these increases in TNF-a were suppressed in IKB Tg mice compared
with NTg mice after DOX therapy (P < 0.05) (Figure 14). Furthermore, DOX
injection led to an increased expression of IL-6 and iNOS in NTg mice compared
to vehicle treated NTg and IKB Tg· mice hearts. Although IKB Tg mice also
decreased expression of both IL-6 and iNOS compared to NTg mice, the protein
expression of iNOS did not display a significant difference in comparison to NTg
mice after DOX therapy (Figure 15 A and 15 B).

CONCLUSIONS
NF-KB regulates gene transcription of many pro-inflammatory cytokines (61) and
myocardial overexpression of NF-KB initiates an inflammatory cascade and
elevates the expression of TNF-a, IL-6, and iNOS. This study shows an increase
in the expression of TNF-a, IL-6, and iN OS in the LV of mouse hearts after DOX
therapy. However, when IKB transgenic mice were treated with DOX, the
induction of TNF-a, IL-6 and iNOS was significantly reduced. Thus inhibition of
NF-KB activity may serve as a potential mechanism for regulating inflammatory
responses.
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CHAPTER VI

AIM#3

Cardiac-Specific Transgenic Inhibition of NF-KB reduces Myocardial
Apoptosis in Doxorubicin-induced Cardiomyopathy

AIM #3 ABSTRACT
Background
Clinical use of DOX is limited by its cardiotoxic effects, which have been shown
to be due to increased oxidative stress and apoptosis. It is unclear if inhibition of
NF-KB has the protective effects on myocardial apoptosis induced by DOX. To
elucidate the possible role of cardiac specific inhibition of NF-KB during the
development of DOX cardiomyopathy, we studied IKB Tg mice by investigating
cardiac apoptosis after induction of DOX-induced cardiomyopathy.
Methods and Results
Age-matched wild-type (Wf, n=14), nontransgenic littermates (NTg, n=14) and
IKB Tg (n=11) mice received intraperitoneal injections of DOX twice over 2 wks
(total

dose

of 15 mg/kg

BW).

Myocardial
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expression

of proapoptotic

proteins Bax and p53 were assessed by Western blot analysis. At 14 days after
DOX therapy, we found a significant increase in the expression of both Bax and
p53 in NTg mice treated with DOX. This increase in expression of Bax and p53
were attenuated by DOX-treated IKB Tg mice.
Conclusions
Cardiac specific inhibition of NF-KB has preventive effects on myocardial
apoptosis induced by DOX, which is probably associated with inhibiting binding
activity of NF-KB and further regulating apoptosis-related protein expression and
translation, and inhibiting myocardial apoptosis. These findings suggest that NFKB is detrimental in DOX-induced cardiomyopathy in that it mediates apoptosis.
These insights might have useful implications for future studies utilizing NF-KB
antagonists for treatment of DOX cardiomyopathy.

INTRODUCTION

Apoptosis (also known as programmed cell death), is a highly conserved
evolutionary event that is crucial for normal development and cell homeostasis. It
is well accepted paradigm that cardiomyocyte apoptosis could playa key role in
the aggravation of heart failure (49, 93). Recent evidence from both in vitro and
in vivo studies demonstrate that exposure to DOX can trigger cardiomyocyte

apoptosis and that this mode of cell death represents the predominant form of
myocyte injury seen in this toxicity (44, 94). Furthermore, morphological features
of hearts from patients with DOX-induced cardiomyopathy suggest that myocyte
cell death may be mediated at least in part through an apoptotic process (58).
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Therefore, the objective of this study was to investigate the antiapoptotic role of
cardiac specific inhibition of NF-KB in DOX-induced myocardial apoptosis. Using
an established model of DOX-induced cardiomyopathy and heart failure in mice,
we examined whether the myocyte loss associated with

DOX-induced

cardiomyopathy is a result of an increase in the incidence of apoptosis. Protein
expression of apoptosis regulatory products such as Bax and p53 were
examined.

MATERIALS AND METHODS
Animals

All animal studies were performed in accordance with the guidelines of the
National Institutes of Health (NIH) Guide for the Care and Use of Laboratory
Animals and University of Louisville. Mice were housed in a facility with a 12
hr/12 hr light/dark cycle and were fed rodent chow and water ad libitum. The
room

was

kept

specific

pathogen-free.

Age-matched

wild-type

(WT),

nontransgenic littermates (NTg) and IkB Tg mice were divided into six groups
based on whether the mice receive either DOX or vehicle. We injected a 7.5
mg/kg dose of DOX intraperitoneally (i.p.) 2 times over 2 wks. Group I, WT
(vehicle, n=6); group II, NTg (vehicle, n=6); group III, Tg (vehicle, n=6); group IV,
WT (DOX, n=14); group V, NTg (DOX, n=14); and group VI, Tg (DOX, n=11).
Groups I, II and III served as control mice and received injections of saline as
vehicle. At the end of study period (14 days after first DOX dose), heart was
removed, the atria and the large vessels were carefully trimmed, and the
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ventricles were separated. The LV (including septum) was dissected and the
tissue was frozen at -70°C for protein expression of Bax and p53.

Preparation of Homogenates and Cytosolic and Membranous Fractions
Homogenates, cytosolic and membranous proteins of heart tissue was prepared
as previously described (90-92). Briefly, myocardial samples were homogenized
for 2 x 10 seconds in buffer A [25 mmol/l Tris . HCI (pH 7.5), 0.5 mmol/l EOTA,
0.5 mmol/l EGTA, 1 mmol/l phenylmethylsulfonyl fluoride, 2 j..Imol/l leupeptin,
1 j..Imol/l pepstatin, 1 j..Imol/l aprotinin, 10 mmol/l NaF, and 100 j..Imol/l dephostatin]
as total cellular homogenates. After that, homogenates were centrifuged at
14,000 9 for 15 mins, and the resulting supernatants were collected as cytosolic
fractions. Pellets were incubated in a lysis buffer (buffer A + 1% Nonidet P-40)
for 4 hrs, centrifuged, and the resulting supernatants used as membranous
fractions. The protein content in the homogenates, cytosolic, and membranous
fractions was determined using the Bradford technique (Bio-Rad).

Western Immunoblotting
The expression of proteins was assessed using standard SOS-PAGE Western
immmunobiotting techniques as previously published methods (90-92). Briefly, 70
j..Ig of cytosolic proteins or membranous proteins were electrophoresed on a
denaturing SOS gel for 2 to 3 hrs. After electrophoresis, the proteins on the gel
were electrophoretically transferred to nitrocellulose membranes (Bio-Rad)
overnight at 4°C. Gel transfer efficiency was carefully recorded by making

50

photocopies of membranes dyed with reversible Ponceau staining; gel retention
was determined by Coomassie blue staining as previously described. The
membranes were incubated in 5% nonfat dry milk in TBST buffer (10 mmol/L
Tris-HCI [pH 7.2], 0.15 mol/L NaCl, and 0.05% Tween-20) followed by incubation
with specific primary antibodies (Santa Cruz Biotechnology, Inc). After extensive
rinsing with TBST buffer, blots were incubated with HRP-conjugated anti-rabbit or
anti-mouse secondary antibodies and developed with the use of an enhanced
chemiluminescence system (ECL kit, Amersham). After washing with TBST
buffer, blots were air-dried and exposed to Kodak films in x-ray cassettes with
intensifying screens.

The

signals

detected

by

immunoblotting

and

the

corresponding records of Ponceau stains of nitrocellulose membranes were
quantitated using an image scanning densitometer (Personal PI, Molecular
Dynamics). Anti-Bax, and anti-p53 antibodies were purchased from Santa Cruz
Biotechnology, Inc.

Statistical Analysis
Data are reported as means ± SEM as previously described methods (90-92).
Measurements were analyzed by ANOVA followed by unpaired Student's t tests
with the Bonferroni correction. In all Western blot analyses, the content of the
specific protein of interest was expressed as a percentage of the corresponding
protein in the anterior LV wall of NTg vehicle-treated mice.
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Figure 16: Western blots of Bax (Panel A) and p53 (Panel B) protein at 2
wks after DOXlsaline treatment in NTg mice compared with IKB Tg mice.
Bar graph shows densitometric quantification from 5 individual hearts per
group. Data are mean ± SEM.
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RESULTS

Attenuation of Bax and p53-mediated apoptosis by cardiac specific
inhibition of NF-KB
As shown in Figure 16A, the cardiac protein expression of the proapoptotic
protein Bax was significantly increased in DOX-treated NTg mice when
compared with healthy sham controls. Cardiac specific inhibition of NF-KB led to
a suppression of DOX-induced Bax over expression. Furthermore, we examined
the changes in protein expression of another proapoptotic factor p53 in NTg mice
and IKB Tg mice with or without DOX treatment. Protein expression of p53 was
significantly increased after DOX administration in NTg mice. Although the
upregulation of p53 was partially prevented by IKB Tg mice, the value did not
reach statistical significance (Figure 16B).

CONCLUSIONS

In the present study, we determined a significant induction of myocardial
apoptosis following DOX administration in mice, which correlated with abnormal
expression and translation of proapoptotic proteins Bax and p53. Our results
showed that cardiac specific inhibition of NF-KB protects myocardium from
apoptosis by inhibiting NF-KB activation in DOX-induced cardiomyopathy, and
further regulating expression, and translation of apoptosis-related genes Bax and
p53. As it is well documented that apoptosis may contribute to cardiomyocyte
loss and structural changes accompanied by up-regulation of the proapoptotic
Bcl-2 family member Bax (95), we examined this protein in mice after DOX
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therapy and found a DOX-mediated increase in the cardiac protein expression of
Bax which was reduced by cardiac specific inhibition of NF-KB. Furthermore,
DOX-induced apoptosis in cardiomyocytes and endothelial cells is more likely
attributable to H2 0 2 production (44, 45), and there is increasing evidence
connecting p53 to intracellular oxidant formation (96, 97). Also, activation of p53
may directly induce activation of Bax gene, which contains a p53 binding site.
Since both superoxide and H2 02 induce p53, we conducted further studies to
detect the protein expression of p53 in DOX-treated hearts. Although the precise
mechanisms of DOX-induced cardiotoxicity remain elusive, there is increasing
evidence that DOX exposure can trigger cardiomyocyte apoptosis, and that this
type of cell death represents the predominant form of myocyte damage seen in
this setting (98). These results suggest that DOX induces myocardial apoptosis
through activation of NF-KB in mice and NF-KB activation requires IKBa
degradation. Therefore, regulation and control of NF-KB activation may be a
powerful therapeutic strategy for reducing DOX-induced myocardial apoptosis.
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CHAPTER VII

SUMMARY AND FUTURE DIRECTIONS

Summary of Findings

In this study, we have shown for the first time that NF-KB contributes to systolic
and diastolic cardiac dysfunction, adverse ventricular remodeling, cardiac
inflammation and apoptosis in experimental DOX-induced cardiomyopathy. In
agreement with other investigators, WT and NTg mice treated with DOX were
found to display severe systolic and diastolic LV dysfunction, resulting in
impaired cardiac function as assessed by echocardiography and invasive
hemodynamics (99-101). In IKB Tg mice treated with DOX, global LV function as
indexed by EF, LVSP, LVEDP, and ±dP/dt, was improved as a result of
enhanced systolic and diastolic performance. In the present study, IKB Tg mice
also showed lower production of proinflammatory cytokines and less activation of
proapoptotic proteins after DOX than did WT and NTg mice. Consequently,
survival rate was higher in IKB Tg mice compared with WT and NTg mice. This
study provides direct evidence of the involvement of NF-KB mediated signaling
pathways in DOX-induced cardiomyopathy. One possible mechanism for
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such a protective effect of NF-KB inhibition is that IKBa expression would directly
inhibit NF-KB activation, resulting in attenuation of the inflammatory response and
subsequent myocardial damage, because the expression of many cytokines,
including TNF-a, IL-6, and iNOS, is regulated by NF-KB activation. These
cytokines are not constitutively expressed in the normal heart. Upregulation and
production of these cytokines represent an intrinsic or innate stress response
against myocardial injury (102, 103). In this investigation, we found that TNF-a,
IL-6, and iNOS levels decreased noticeably in IKB Tg mice compared with
and

NTg

mice,

further

indicating

that

IKBa

overexpression

wr

attenuates

inflammatory response mediated by DOX-induced cardiomyopathy.
As inflammation might also be associated with induction of apoptosis and as
TNF-a induces increase in reactive oxygen species production and oxidative
stress in cardiomyocytes and lead to apoptosis (49, 104), we further investigated
the expression of proapoptotic proteins Bax and p53 in mice hearts after DOX
therapy. Since cardiomyocytes are terminally differentiated cells, any loss of
these cells due to cell death can have critical functional consequences (105). In
agreement with in vitro and in vivo studies using myocytes, we also found a
marked up-regulation of the pro-apoptotic protein p53 14 days after DOX
administration in our model (106, 107). This effect was blunted in IKB Tg mice,
suggesting that NF-KB contributes to pro-apoptotic activation in DOX-induced
cardiomyopathy. Furthermore, to investigate possible mechanisms, which may
lead to attenuated apoptosis in DOX-treated IKB Tg mice, we measured the
expression of protein Bax, which is a pivotal regulator of mitochondrial apoptosis.
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The Bax content of IKB Tg mice were significantly decreased when compared to

wr and NTg mice suggesting protection from apoptosis due to NF-KB deficiency.
In summary, the effects of DOX-induced cardiomyopathy included cardiac
dysfunction, detrimental cardiac remodeling,

inflammatory response,

and

apoptosis leading to LV dysfunction. NF-KB deficiency attenuated these
mechanisms known to be critical for the development of DOX-induced heart
failure. Our data demonstrate a relevant role of NF-KB in the development of this
disease under experimental conditions. We have shown the preservation of
cardiac function, increase in survival rate, and attenuation of myocardial
apoptosis after DOX in IKB Tg mice. These findings strongly implicate that DOX
induces myocardial apoptosis through activation of NF-KB in mice and NF-KB
activation require IKBa degradation.

Future Directions
In clinical settings, the typical time course of DOX-induced cardiac toxicity is over
years after multiple low dose treatments. As such, these temporal differences as
well as other differences between rodents and humans do not allow our results to
be directly extrapolated to the clinical arena (52, 108, 109). However, further
clinical trials and basic research will have to verify this concept and furthermore,
it needs to be elucidated whether or not NF-KB inhibition counteracts with the
oncological effect of DOX. In these lines, we need better understanding of the
molecular mechanisms underlying DOX-induced cardiac toxicity. Aside from
mechanistic aspects, the present investigations suggest the cardioprotective role
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of NF-KB inhibition in DOX-induced cardiomyopathy, which may be of therapeutic
benefit for patients receiving DOX. Thus, cardiac specific NF-KB inhibition might
constitute a potentially new therapeutic option to prevent DOX-induced
cardiotoxicity.
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